UCP1 and obesity disorder: These AKG‐induced anti‐obesity effects include decreases in body weight gain (Fig 6A), fat mass (Fig 6C and D), gWAT and iWAT weight (Fig 6E and F), adipocyte size of gWAT and iWAT (Appendix Fig S2J and K), and RER (Fig 6K and L), as well as increases in lean mass (Fig 6C and D), oxygen consumption (Fig 6I and J), ATGL protein in gWAT (Fig 6G and H), phosphorylation of HSL in both iWAT and gWAT (Fig 6G and H, Appendix Fig S2L and M), and UCP1 protein in BAT (Appendix Fig S2I).